Cargando…
Off‐target inhibition by active site‐targeting SHP2 inhibitors
Due to the involvement of SHP2 (SH2 domain‐containing protein‐tyrosine phosphatase) in human disease, including Noonan syndrome and cancer, several inhibitors targeting SHP2 have been developed. Here, we report that the commonly used SHP2 inhibitor NSC‐87877 does not exhibit robust inhibitory effect...
Autores principales: | Tsutsumi, Ryouhei, Ran, Hao, Neel, Benjamin G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6120237/ https://www.ncbi.nlm.nih.gov/pubmed/30186742 http://dx.doi.org/10.1002/2211-5463.12493 |
Ejemplares similares
-
Corrigendum to: Off‐target inhibition by active site‐targeting SHP2 inhibitors
por: Tsutsumi, Ryouhei, et al.
Publicado: (2019) -
Assay to visualize specific protein oxidation reveals spatio-temporal regulation of SHP2
por: Tsutsumi, Ryouhei, et al.
Publicado: (2017) -
Targeting
SHP2 with an Active Site Inhibitor Blocks
Signaling and Breast Cancer Cell Phenotypes
por: Lade, Dhanaji M., et al.
Publicado: (2023) -
Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies
por: Song, Zhendong, et al.
Publicado: (2021) -
Targeting a Cryptic Allosteric Site for Selective
Inhibition of the Oncogenic Protein Tyrosine Phosphatase Shp2
por: Chio, Cynthia M., et al.
Publicado: (2014)